These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35257596)

  • 1. Treatment of Opioid Use Disorder in Canadian Psychosocial Addiction Programs: A National Survey of Policy, Attitudes, and Practice.
    Hodgins DC; Budd M; Czukar G; Dubreucq S; Jackson LA; Rush B; Quilty LC; Adams D; Cameron Wild T
    Can J Psychiatry; 2022 Aug; 67(8):638-647. PubMed ID: 35257596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Canadian and United States opioid agonist therapy policies.
    Priest KC; Gorfinkel L; Klimas J; Jones AA; Fairbairn N; McCarty D
    Int J Drug Policy; 2019 Dec; 74():257-265. PubMed ID: 30765118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?
    Russell C; Lange S; Kouyoumdjian F; Butler A; Ali F
    Harm Reduct J; 2022 Aug; 19(1):89. PubMed ID: 35948961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses.
    Rice D; Corace K; Wolfe D; Esmaeilisaraji L; Michaud A; Grima A; Austin B; Douma R; Barbeau P; Butler C; Willows M; Poulin PA; Sproule BA; Porath A; Garber G; Taha S; Garner G; Skidmore B; Moher D; Thavorn K; Hutton B
    PLoS One; 2020; 15(12):e0244401. PubMed ID: 33370393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
    Van Hout MC; Crowley D; McBride A; Delargy I
    BMC Fam Pract; 2018 Jun; 19(1):103. PubMed ID: 29960593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
    Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
    Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
    Crowley D; Delargy I
    Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.
    Morozova O; Crawford FW; Cohen T; Paltiel AD; Altice FL
    Addiction; 2020 Mar; 115(3):437-450. PubMed ID: 31478285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Punitive discontinuation of opioid agonist therapy during incarceration.
    Marmel A; Bozinoff N
    Int J Prison Health; 2020 Aug; 16(4):337-342. PubMed ID: 33634666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
    Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
    Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital policies for opioid use disorder treatment: A policy content analysis and environmental scan checklist.
    Priest KC; Englander H; McCarty D
    Gen Hosp Psychiatry; 2021; 70():18-24. PubMed ID: 33667810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
    Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
    Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran.
    Nakhaeizadeh M; Abdolahinia Z; Sharifi H; Mirzazadeh A; Haghdoost AA; Shokoohi M; Baral S; Karamouzian M; Shahesmaeili A
    Harm Reduct J; 2020 Jul; 17(1):50. PubMed ID: 32698875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.